<p>藥明康德（NYSE:RDY - 獲取免費報告）在週四發佈給客户和投資者的研究報告中，被滙豐的股票研究分析師從 “持有” 評級上調至 “買入” 評級。該公司目前對該股票的目標價為 16.90 美元。滙豐的目標價意味着該公司當前價格有 14.50% 的潛在上漲空間。</p>
<ul>
<li>Teva Pharmaceuticals 股票：發掘這款仿製藥的價值</li>
</ul>
<p>另外，華爾街 Zen 在 5 月 8 日的研究報告中將藥明康德的股票評級從 “持有” 上調至 “買入”。</p>
<p><strong>查看我們最新的 RDY 股票分析</strong></p>
<h2>藥明康德股價上漲 0.7%</h2>
<ul>
<li>2 只被忽視的股票，盈利超預期但股價下跌</li>
</ul>
<p>週四，RDY 的開盤價為 14.76 美元。該公司的市值為 123.2 億美元，市盈率為 23.50，貝塔值為 0.33。公司的 50 日簡單移動平均線為 13.77 美元，200 日簡單移動平均線為 14.02 美元。藥明康德的 1 年最低價為 12.26 美元，1 年最高價為 16.89 美元。該公司的債務股本比為 0.02，流動比率為 1.92，速動比率為 1.38。</p>
<p>藥明康德（NYSE:RDY - 獲取免費報告）最後一次公佈季度財報是在 5 月 9 日，週五。該公司報告本季度每股收益為 0.22 美元，超出分析師一致預期的 0.20 美元，超出幅度為 0.02 美元。該公司本季度的收入為 9.9617 億美元，而一致預期為 837 億美元。藥明康德的股本回報率為 17.87%，淨利潤率為 17.25%。分析師預計藥明康德在當前財政年度將發佈 0.8 美元的每股收益。</p>
<h2>藥明康德的機構交易</h2>
<ul>
<li>製藥公司 GSK：成為更健康的價值股</li>
</ul>
<p>一些機構投資者和對沖基金最近增加或減少了對 RDY 的持股。Costello Asset Management INC 在第一季度購買了藥明康德的新股份，價值 26,000 美元。EverSource Wealth Advisors LLC 在第四季度將其在藥明康德的持股增加了 423.3%。EverSource Wealth Advisors LLC 現在擁有 1,863 股該公司的股票，價值 29,000 美元，此前在上個季度增持了 1,507 股。Glass Jacobson Investment Advisors llc 在第四季度將其在藥明康德的持股增加了 400.0%。Glass Jacobson Investment Advisors llc 現在擁有 2,000 股該公司的股票，價值 32,000 美元，此前在上個季度增持了 1,600 股。POM Investment Strategies LLC 在第四季度將其在藥明康德的持股增加了 400.0%。POM Investment Strategies LLC 現在擁有 2,275 股該公司的股票，價值 36,000 美元，此前在此期間增持了 1,820 股。最後，Farther Finance Advisors LLC 在第四季度將其在藥明康德的持股增加了 461.0%。Farther Finance Advisors LLC 現在擁有 2,547 股該公司的股票，價值 40,000 美元，此前在此期間增持了 2,093 股。對沖基金和其他機構投資者持有該公司 3.85% 的股份。</p>
<h2>關於藥明康德</h2>
<p>（獲取免費報告）</p>
<p>藥明康德有限公司及其子公司在全球範圍內作為一家綜合製藥公司運營。它通過全球仿製藥、製藥服務和活性成分（PSAI）及其他部門運營。公司的全球仿製藥部門生產和銷售處方藥和非處方藥成品，這些產品以品牌名稱或作為具有治療等效性的仿製成品劑型進行市場營銷，同時還參與生物製藥業務。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過藥明康德</li>
<li>什麼是股息之王？</li>
<li>Alphabet 股票分析：接下來會是牛市還是熊市？</li>
<li>房地產投資信託是否值得在您的投資組合中佔有一席之地？</li>
<li>3 只盈利大、風險平衡的公用事業股票</li>
<li>如何投資科技股以及值得考慮的頂級科技股</li>
<li>NVIDIA 重奪榜首；FOMO 是其持續上漲的原因</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
<p>在考慮藥明康德之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而藥明康德並不在名單上。</p>
<p>雖然藥明康德目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

如瑞迪博士

<p>滙豐銀行將藥明康德（NYSE:RDY）的評級從 “持有” 上調至 “買入”，目標價格設定為 16.90 美元，意味着潛在上漲空間為 14.50%。該股票開盤價為 14.76 美元，市值為 123.2 億美元。公司在上一季度報告的每股收益為 0.22 美元，超出預期。機構投資者最近顯著增加了對公司的持股。藥明康德作為一家綜合製藥公司，專注於仿製藥和活性成分</p>

<p>Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) was upgraded by equities research analysts at HSBC from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report issued to clients and investors on Thursday. The firm presently has a $16.90 target price on the stock. HSBC's target price would indicate a potential upside of 14.50% from the company's current price.</p>
<div class="lb-trans"><p>藥明康德（NYSE:RDY - 獲取免費報告）在週四發佈給客户和投資者的研究報告中，被滙豐的股票研究分析師從 “持有” 評級上調至 “買入” 評級。該公司目前對該股票的目標價為 16.90 美元。滙豐的目標價意味着該公司當前價格有 14.50% 的潛在上漲空間。</p>
</div><ul>
<li>Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharmaceuticals 股票：發掘這款仿製藥的價值</li>
</ul>
</div><p>Separately, Wall Street Zen raised shares of Dr. Reddy's Laboratories from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Thursday, May 8th.</p>
<div class="lb-trans"><p>另外，華爾街 Zen 在 5 月 8 日的研究報告中將藥明康德的股票評級從 “持有” 上調至 “買入”。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on RDY</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 RDY 股票分析</strong></p>
</div><h2>Dr. Reddy's Laboratories Trading Up 0.7%</h2>
<div class="lb-trans"><h2>藥明康德股價上漲 0.7%</h2>
</div><ul>
<li>2 overlooked stocks that crushed earnings but traded lower</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只被忽視的股票，盈利超預期但股價下跌</li>
</ul>
</div><p>RDY opened at $14.76 on Thursday. The firm has a market capitalization of $12.32 billion, a price-to-earnings ratio of 23.50 and a beta of 0.33. The company's 50 day simple moving average is $13.77 and its two-hundred day simple moving average is $14.02. Dr. Reddy's Laboratories has a 1-year low of $12.26 and a 1-year high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38.</p>
<div class="lb-trans"><p>週四，RDY 的開盤價為 14.76 美元。該公司的市值為 123.2 億美元，市盈率為 23.50，貝塔值為 0.33。公司的 50 日簡單移動平均線為 13.77 美元，200 日簡單移動平均線為 14.02 美元。藥明康德的 1 年最低價為 12.26 美元，1 年最高價為 16.89 美元。該公司的債務股本比為 0.02，流動比率為 1.92，速動比率為 1.38。</p>
</div><p>Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported $0.22 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.02. The firm had revenue of $996.17 million for the quarter, compared to the consensus estimate of $83.70 billion. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Analysts expect that Dr. Reddy's Laboratories will post 0.8 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>藥明康德（NYSE:RDY - 獲取免費報告）最後一次公佈季度財報是在 5 月 9 日，週五。該公司報告本季度每股收益為 0.22 美元，超出分析師一致預期的 0.20 美元，超出幅度為 0.02 美元。該公司本季度的收入為 9.9617 億美元，而一致預期為 837 億美元。藥明康德的股本回報率為 17.87%，淨利潤率為 17.25%。分析師預計藥明康德在當前財政年度將發佈 0.8 美元的每股收益。</p>
</div><h2>Institutional Trading of Dr. Reddy's Laboratories</h2>
<div class="lb-trans"><h2>藥明康德的機構交易</h2>
</div><ul>
<li>Drugmaker GSK: Becoming a Healthier Value Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>製藥公司 GSK：成為更健康的價值股</li>
</ul>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in RDY. Costello Asset Management INC purchased a new position in shares of Dr. Reddy's Laboratories during the first quarter worth $26,000. EverSource Wealth Advisors LLC lifted its stake in Dr. Reddy's Laboratories by 423.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock worth $29,000 after acquiring an additional 1,507 shares in the last quarter. Glass Jacobson Investment Advisors llc lifted its stake in Dr. Reddy's Laboratories by 400.0% during the 4th quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock worth $32,000 after acquiring an additional 1,600 shares in the last quarter. POM Investment Strategies LLC boosted its holdings in Dr. Reddy's Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after acquiring an additional 1,820 shares during the period. Finally, Farther Finance Advisors LLC boosted its holdings in Dr. Reddy's Laboratories by 461.0% during the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock valued at $40,000 after acquiring an additional 2,093 shares during the period. Hedge funds and other institutional investors own 3.85% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近增加或減少了對 RDY 的持股。Costello Asset Management INC 在第一季度購買了藥明康德的新股份，價值 26,000 美元。EverSource Wealth Advisors LLC 在第四季度將其在藥明康德的持股增加了 423.3%。EverSource Wealth Advisors LLC 現在擁有 1,863 股該公司的股票，價值 29,000 美元，此前在上個季度增持了 1,507 股。Glass Jacobson Investment Advisors llc 在第四季度將其在藥明康德的持股增加了 400.0%。Glass Jacobson Investment Advisors llc 現在擁有 2,000 股該公司的股票，價值 32,000 美元，此前在上個季度增持了 1,600 股。POM Investment Strategies LLC 在第四季度將其在藥明康德的持股增加了 400.0%。POM Investment Strategies LLC 現在擁有 2,275 股該公司的股票，價值 36,000 美元，此前在此期間增持了 1,820 股。最後，Farther Finance Advisors LLC 在第四季度將其在藥明康德的持股增加了 461.0%。Farther Finance Advisors LLC 現在擁有 2,547 股該公司的股票，價值 40,000 美元，此前在此期間增持了 2,093 股。對沖基金和其他機構投資者持有該公司 3.85% 的股份。</p>
</div><h2>About Dr. Reddy's Laboratories</h2>
<div class="lb-trans"><h2>關於藥明康德</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.</p>
<div class="lb-trans"><p>藥明康德有限公司及其子公司在全球範圍內作為一家綜合製藥公司運營。它通過全球仿製藥、製藥服務和活性成分（PSAI）及其他部門運營。公司的全球仿製藥部門生產和銷售處方藥和非處方藥成品，這些產品以品牌名稱或作為具有治療等效性的仿製成品劑型進行市場營銷，同時還參與生物製藥業務。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Dr. Reddy's Laboratories</li>
<li>What is a Dividend King?</li>
<li>Alphabet Stock Analysis: What's Next—Bull or Bear Market?</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>3 Utilities Stocks With Big Earnings, Balanced Risk</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過藥明康德</li>
<li>什麼是股息之王？</li>
<li>Alphabet 股票分析：接下來會是牛市還是熊市？</li>
<li>房地產投資信託是否值得在您的投資組合中佔有一席之地？</li>
<li>3 只盈利大、風險平衡的公用事業股票</li>
<li>如何投資科技股以及值得考慮的頂級科技股</li>
<li>NVIDIA 重奪榜首；FOMO 是其持續上漲的原因</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Dr. Reddy's Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
</div><p>Before you consider Dr. Reddy's Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮藥明康德之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而藥明康德並不在名單上。</p>
</div><p>While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然藥明康德目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

如瑞迪博士實驗室（NYSE:RDY）被滙豐銀行提升至 “買入” 評級